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Abstract
Background: Disseminated peritoneal adenomucinosis (DPAM) patients often have a history of appendectomy
with identification of an incidental mucinous neoplasm (low-grade appendiceal mucinous neoplasm (LAMN)). The
rate of developing DPAM is not well established.
Methods: Twenty-two patients with incidental LAMN were identified and monitored with cancer markers and CT
every 4–6 months. Laparoscopy with peritoneal washing was performed in patients either in the event of
radiographic disease or after 12 months in absence of radiographic disease. The rate of detecting peritoneal
metastasis was determined for CT scan and laparoscopy.
Results: Peritoneal metastasis was detected in 5 (23 %) patients. Occult disease was detected in four patients at
laparoscopy without a detectable disease on CT scan. One patient developed radiographic progression at 6 months
confirmed with laparoscopy. Four patients were treated with cytoreductive surgery (CRS)/HIPEC and one with CRS
only. The 17 patients with negative laparoscopy remain disease free with a median follow-up of 50 months.
Conclusions: The rate of peritoneal metastasis in incidental LAMN patients was 23 %. Laparoscopy was the primary
screening tool identifying occult metastasis. The median PCI of 7 was low, and all the patients underwent R0/R1
resections. This study revealed 1 in every 4.4 patients with LAMN may develop PMP. Longer follow-up and further
patient surveillance is warranted.
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Background
Appendix tumors are rare, representing less than 1 % of
gastrointestinal cancers and incidentally detected in ap-
proximately 1 % of appendectomy specimens [1–4]. The
two most common histologies identified are mucinous
and carcinoid tumors [5, 6]. Carcinoid tumors, like colo-
rectal cancer, have a propensity for lymphatic and
hematogenous spread [7]. Conversely, mucinous tumors
infrequently exhibit hematogenous spread, and nodal in-
volvement is rare in low-grade mucinous tumors [8, 9].
Peritoneal dissemination is the most common form of
metastasis observed in low-grade appendiceal mucinous
neoplasms (LAMN), and this condition is called pseudo-
myxoma peritonei (PMP). PMP has been split into low-
and high-grade diseases which has been further subclas-
sified by Ronnett into disseminated peritoneal adenomu-
cinosis (DPAM) (low grade), peritoneal mucinous
carcinomatosis (PMCA)-I (intermediate grade), and
PMCA (high grade) which characterize PMP along a
continuum of biological behavior [9].
Majority of patients who present with low-grade
PMP are symptomatic with bulky peritoneal disease
[10]. The slow-growing non-invasive biology of these
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tumors contributes to the development of extensive
peritoneal disease before patients seek medical atten-
tion for clinical symptoms. This indolent pattern of
growth not only affords patients with PMP an oppor-
tunity for symptom palliation but majority can
achieve long-term remission with cytoreductive sur-
gery and hyperthermic intraperitoneal chemotherapy
(CRS/HIPEC) [11].
Cytoreductive procedures often require extensive
operative time and extended recovery. The factors
predicting long-term survival with DPAM are well
established and include disease extent measured by
peritoneal cancer index (PCI), ability to achieve opti-
mal cytoreduction quantified by completeness of
cytoreduction (CC) score or R score (CC-0/CC-1 or
R0/R2a), and early referral to centers with experi-
ence in CRS surgery [12–14].
Optimal tumor cytoreduction can be achieved in 70–
90 % of DPAM patients, but this typically requires exten-
sive cytoreductive procedures with multivisceral organ re-
sections, prolonged hospital stay, and post-operative
morbidity and mortality rates of 30–50 % and 3–7 %, re-
spectively [13]. Many patients who develop symptomatic
low-grade PMP have a history of appendectomy with an
incidental LAMN identified. Given the low incidence of
LAMN tumors, there is a paucity of data that defines the
rate of LAMN progression to PMP of the DPAM subtype,
and like most rare tumors, there is currently no consensus
on follow-up guidelines. In spite of these obstacles, the de-
velopment of a surveillance strategy in LAMN may not
only provide insight into the rate of PMP development
but facilitate early detection of occult peritoneal metasta-
sis in LAMN patients and improve outcomes in PMP pa-
tients. Currently, only one retrospective population study
in the Netherlands reported an observed PMP incidence
of 20 % in 547 patients with LAMN lesions. Majority of
the PMP events were detected within 24 months, but in a
few cases, PMP occurred after 2 years [15]. As a result,
this group recommends performing cross-sectional im-
aging for at least 5 years in patients with incidental
LAMN tumors. Since CT imaging has known limitations
in the detection of peritoneal metastasis, a second modal-
ity, diagnostic laparoscopy, was added to the surveillance
regimen to determine if occult disease could be identified
in patients in the absence of CT-detectable disease. Here,
we report the results of this surveillance strategy.
Methods
Patient population
A retrospective chart review was conducted on patients
referred for management of LAMN. In this study, low-
grade mucinous tumors were defined by the grading sys-
tem reported by Carr et al. and Misrdraji et al., recently
adopted by the Peritoneal Surface Oncology Group
International (PSOGI) [16–19]. All cases included in this
analysis had mucin with low-grade architectural features,
“pushing alteration” of the muscularis mucosa or wall,
and when pathology was reviewed at our institutions,
the presence of perforation, extra-appendiceal mucin,
and extra-appendiceal cells was reported. Twenty-two
LAMN patients were identified, diagnosed between June
2006 and May 2013, and comprehensive pathology re-
ports were available in 20 out of the 22 patients. In two
LAMN cases, the comprehensive pathology reports were
not available.
Surveillance strategy
All patients had a baseline CT scan performed prior to
their appendectomy, and these images were reviewed at
first consultation (Fig. 1). All outside medical records
and pathology and imaging reports were reviewed. Base-
line tumor markers were obtained at the first consult-
ation which included CA-19-9, CEA, and CA-125. The
patients were re-evaluated every 4–6 months with clin-
ical exams, abdomen and pelvis CT scans, and tumor
markers. If any radiographic abnormality was reported
by the reading radiologist consistent with concerns of
peritoneal metastasis, patients were taken for diagnostic
laparoscopy to pathologically document disease progres-
sion. After 12 months of surveillance, all the patients
underwent diagnostic laparoscopy to determine if occult
peritoneal metastasis could be identified in the absence
of CT-detectable disease. At the time of laparoscopy,
PCI zones were evaluated for peritoneal implantation
and peritoneal washings were performed. Any suspicious
nodules identified were biopsied and sent for patho-
logical evaluation. If pathologically confirmed peritoneal
disease was detected, the patient was offered definitive
CRS/HIPEC. All the patients with positive findings
elected to undergo CRS/HIPEC except for one patient
who only underwent CRS without HIPEC.
Clinical and outcomes data analysis
Demographic information was collected on all LAMN pa-
tients including age, sex, and additional procedures per-
formed prior to referral and any administration of
chemotherapy by referring providers. The appendectomy
proximal margin was negative in all 22 specimens, and in
20/22 cases, data was available to determine the presence
of perforation or extra-appendiceal mucin and/or extra-
appendiceal cells. Following diagnostic laparoscopy, ad-
verse events, cytology results, and rate of detection of
peritoneal implants were determined. Finally, we calcu-
lated median follow-up time, overall survival, and current
status of disease.
In LAMN patients where peritoneal metastasis was
identified, all underwent CRS/HIPEC except for one pa-
tient who underwent CRS alone. PCI score (tumor
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burden) [20], CC score, length of stay (LOS), overall sur-
vival, and disease-free survival status were determined.
Right hemicolectomy, partial peritonectomy sites and
rates, visceral organ resection rates, and total resections
performed which included peritonectomy procedures
were also calculated. The organ resections performed in-
cluded omentectomy, right colectomy, cholecystectomy,
distal pancreatectomy, splenectomy, and non-anatomical
hepatectomy or liver capsule resection. All peritonec-
tomies were limited partial resections, and the sites in-
cluded the diaphragm, colic gutters, and pelvis.
Morbidity and mortality were quantified by the Clavien-
Dindo classification grades I–V [21].
Results
Demographics of surveillance group and serology results
The mean age at diagnosis for the 22 LAMN patients
was 53, and 55 % (12) were males. Twenty-one patients
(95 %) underwent appendectomy for their disease. One
patient (5 %) underwent right hemicolectomy and chole-
cystectomy and was also started on chemotherapy prior
to referral. Following diagnostic laparoscopy, all the pa-
tients were discharged within 23 h of the procedure
without any adverse events. In all the 22 patients, CEA,
CA-19-9, and CA-125 levels were within normal limits
and no patient experienced any marker elevation.
LAMN appendix pathology features, rates and sites of PM
implants, and cytology results
Comprehensive pathological characteristics were avail-
able in 91 % (20/22) of the patients (Table 1). Appendix
perforation and extra-appendiceal mucin were identified
in 90 % (18/20) of the specimens. In these 18 patients
with perforation and mucin extravasation, 5/18 (28 %)
developed peritoneal metastasis while 13/18 (72 %) had
no evidence of peritoneal metastasis at diagnostic lapar-
oscopy. Extra-appendiceal cells were identified in 10/20
of the patients, 4/10 (40 %) developed peritoneal metas-
tasis while 6/10 (60 %) had no evidence of peritoneal
metastasis. The overall rate of peritoneal metastasis was
5/22 (23 %) (Fig. 2); perforation and extra-appendiceal
mucin were present in 5/5 (100 %) of the patients, and
extra-appendiceal cells were present in 4/5 (82 %) of the
patients (Table 1). At laparoscopy, cytology was positive
for cells in 60 % (3/5) of the patients with peritoneal me-
tastasis (Table 1).
The most frequent PCI zones with occult metastases
were zones 0 and 1 with disease identified in all 5 pa-
tients (100 %). Figure 3 provides a comprehensive de-
scription of the sites involved for each patient and the
rate of involvements in each PCI zone.
Outcomes in LAMN patients without PMP
All 17 patients had no evidence of disease or pathology
on CT imaging, tumor marker serology was within nor-
mal limits, and there was no detectable tumor at lapar-
oscopy. Tumor cytology in this group of patients was
negative for tumor or mucin in peritoneal washings.
One patient underwent a second laparoscopy at the 2-
year mark because of inflammatory changes found at the
first laparoscopy, and biopsies at the first laparoscopy re-
vealed inflammatory nodules. The second laparoscopy
revealed resolution of the inflammatory changes, and no
disease or inflammation was identified. The median
follow-up time was 50 (20–106) months, and none of
the patients developed clinical progression during the
follow-up period.
Outcomes in LAMN patients with PMP
Five patients (23 %) were identified who developed peri-
toneal metastasis (Fig. 2). The patient that underwent
right hemicolectomy (RHC) and cholecystectomy and
received FOLFOX chemotherapy prior to referral had
radiographic progression and evidence of DPAM at
6 months following LAMN diagnosis with evidence of
omental nodularity. Laparoscopy was performed based
on the CT scan and confirmed peritoneal metastasis.
The radiographic PCI in this case was 8, and the PCI at
exploration was 14 (Table 2, patient #4). In the other
four cases with negative CT results, occult peritoneal
Fig. 1 Surveillance algorithm for LAMN patients
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disease was identified at laparoscopy. The sites of de-
tected disease can be found in Fig. 3.
The rate of RHC was 40 % (2/5), with one performed
prior to referral and one performed at the time of CRS/
HIPEC because of concerns for gross surface disease
(Table 2). In both cases, the pathological analysis of the
specimens revealed no surface or nodal involvement. In
all cases (5/5), a CC-0/CC-1 was achieved, and Table 2
provides each patient’s PCI scores, organ resections,
peritonectomy rates, and LOS, while Fig. 3 provides the
PCI zones of disease detection for each patient. Median
PCI and total organ resection values were 7 and 3, re-
spectively, reflecting the limited disease burden. The me-
dian LOS was 7 days, and no post-operative deaths
occurred with only one patient experiencing a grade II
Clavien-Dindo adverse medical event, hypertension re-
quiring an esmolol drip.
In 4/5 patients treated with CRS/HIPEC, all the pa-
tients are alive without disease recurrence with median
follow-up of 50 months. In the patient who elected to
have CRS alone, disease recurrence occurred at
24 months after cytoreduction (36 months from diagno-
sis). The recurrence was detected on CT imaging, and
the patient had no clinical symptoms. The patient
underwent a second procedure with a PCI score of 19,
and CC-1 cytoreduction was achieved. The patient is
currently alive without recurrence or progression.
Fig. 2 Incidence of detection of peritoneal metastasis in
LAMN patients
Table 1 Individual descriptive appendectomy pathology and cytology results at the time of laparoscopic surveillance
LAMN without DPAM Perforation Extra-appendiceal mucin Extra-appendiceal cells Cytology at laparoscopy
1 + + − −
2 + + + −
3 + + + −
4 + + − −
5 + + + −
6 + + + −
7 + + + −
8 + + − −
9 + + − −
10 − − − −
11 + + − −
12 − − − −
13 + + + −
14 + + − −
15 + + − −
16 N/A N/A N/A −
17 N/A N/A N/A −
Total 13/15 (87 %) 13/15 (87 %) 6/15 (40 %) 0/17 (0 %)
LAMN with DPAM Perforation Extra-appendiceal mucin Extra-appendiceal cells Cytology at laparoscopy
1 + + + +
2 + + − −
3 + + + −
4 + + + +
5 + + + +
Total 5/5 (100 %) 5/5 (100 %) 4/5 (80 %) 3/5 (60 %)
All patients 18/20 (90 %) 18/20 (90 %) 10/20 (50 %) 3/22 (14 %)
Descriptive pathology results were not available in two patients labeled N/A
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Discussion
The optimal management of incidental LAMN tumors
had been a challenging area to define because of the low
incidence and indolent behavior of LAMN tumors that
develop peritoneal metastasis resulting in low-grade
PMP, DPAM. The goal of this study was to longitudin-
ally follow patients with only LAMN tumors, excluding
all other histologies, and evaluate these patients for the
development of peritoneal metastasis with imaging and
laparoscopy. It has been established that low-grade mu-
cinous appendix tumors are the most common primary
tumor site resulting in the development of low-grade
PMP, with very minimal risk of nodal or hematogenous
dissemination [22]. What has not been clearly estab-
lished is the rate at which LAMN tumors disseminate
and develop low-grade PMP. In this series of 22 patients,
occult peritoneal metastasis was detected in 5 (23 %) pa-
tients. Only one case was detected on imaging and con-
firmed with laparoscopy, while 80 % (4/5) of the cases
were only detected by laparoscopy. Although this is a
small series, this observed rate of PMP is consistent with
the rate reported by Smeenk et al., where a PMP rate of
20 % was observed in patients with LAMN histology
[15]. This correlation of event rates of PMP development
provides support that laparoscopy may be a useful
screening tool for LAMN patients given the limitations
of the small sample size.
Current surveillance recommendations for the man-
agement of low-grade mucinous appendix tumors range
from no routine imaging to imaging every 6–12 months,
or even consideration of CRS/HIPEC for patients with
perforated disease and extravasated mucin. This data re-
vealed that a CT scan as a surveillance tool may be inad-
equate for the detection of early PMP. This is consistent
with other data demonstrating the CT scan often under-
stages the volume of peritoneal disease in patients with
known peritoneal metastasis [19]. MRI was not per-
formed in these patients, but recent data demonstrates it
may be a more sensitive tool for detection of peritoneal
metastasis [23, 24]. As a result, we have switched to
Fig. 3 Map and table of metastasis based on PCI zones
Table 2 RHC status, PCI score, organs resected, LOS, and CC score for the LAMN group with PMP
LAMN with DPAM RHC PCI # of organs resected Peritonectomies LOS CC score HIPEC Recurrence
1 + 8 2 2 7 1 + −
2 − 7 2 2 7 0 + −
3 − 5 1 3 6 0 − +
4 +a 14 2 3 8 1 + −
5 − 7 1 4 8 1 + −
All RHC specimens were negative. All peritonectomies were partial resection not complete in PCI zones
aIndicates RHC was done prior to CRS/HIPEC
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patients and only perform CT imaging when patients can-
not tolerate MRI or when motion artifacts may limit
interpretation.
It has been suggested in the setting of perforated ap-
pendix with extra-appendiceal mucin and/or cells in
LAMN patients consider CRS/HIPEC [25]. The compre-
hensive pathological analysis revealed that these features
were present in all patients who develop PMP; however,
this feature was present in 90 % (18/20) of all the speci-
mens. Specifically, 13/18 patients with these features
were identified without detectable occult peritoneal me-
tastasis at laparoscopy. If CRS/HIPEC was performed for
all patients with perforation and extra-appendiceal
mucin, 72 % (13/18) of the patients with this feature po-
tentially may have been over-treated and subjected to
the risks of CRS/HIPEC. A similar result was observed
in patients with extra-appendiceal cells where it was
identified in 10/20 cases and 60 % (6/10) of the patients
would have been treated with CRS/HIPEC that did not
develop DPAM. Delayed recurrences are a real concern,
and continued follow-up is important. However, none of
the 17 patients without evidence of occult peritoneal
metastasis have developed PMP with a median follow-up
period of 50 months, and they continue to undergo ac-
tive imaging surveillance every 12 months.
Laparoscopy appears to be a promising screening tool
in LAMN patients, but it is an invasive procedure with
surgical risks. In this series, no major adverse events oc-
curred, but bowel injury, port site infections, and hernia
are complications that must be balanced with the bene-
fits of early detection. Larger patient series will be neces-
sary to address this question. There are limitations to
this study including the small sample size and retro-
spective data collection. In spite of these limitations, the
observed rate of PMP is consistent with the rate re-
ported in the literature based on a study consisting 574
patients with LAMN, wherein 114 (20 %) developed
PMP, and this provides some validation of the results ob-
served [15]. The benefits of early detection include
asymptomatic detection resulting in low PCI index at
surgery, 100 % optimal cytoreduction rate, and poten-
tially a small surgical procedure evident by a low rate of
organ resections. The impact on survival is not clear
since the current follow-up is only 50 months, but given
the favorable factors of low PCI and CC-0/CC-1 in all
cases, this would support a more favorable outcome
[14]. Interestingly, the only recurrence occurred in one
patient who did not receive HIPEC after 3 years of
follow-up. It is not clear what other factors played a role
in this patient’s recurrence, but this observation provides
evidence that these occult tumors are biologically active
and can progress/recur over time. This patient is cur-
rently in remission following the second CRS with
HIPEC.
Based on this preliminary data, our group is establish-
ing a prospective registry trial employing this surveil-
lance protocol utilizing cross-sectional imaging (MRI or
CT) every 4–6 months and serological marker assess-
ment and offering all patients laparoscopy after 1 year of
imaging surveillance or in the event of radiologic find-
ings of peritoneal metastasis. Through a multi-
institutional collaborative effort, we hope that continued
research in this area will more clearly define the inci-
dence of PMP and result in early detection of the
syndrome.
Conclusions
The rate of peritoneal metastasis in incidental LAMN
patients was 23 %, and laparoscopy was the primary
screening tool identifying occult metastasis. Given the
favorable prognosis of early detection and treatment of
PMP, DPAM, further trials utilizing a surveillance strat-
egy of laparoscopy, serological markers, and cross-
sectional imaging are warranted.
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